To understand how Chinese high-tech and pharmaceutical products could reach the US in 2025 without punitive tariffs, despite the new tariffs against China, one must consider current trade dynamics, the structure of global supply chains, and legal as well as logistical possibilities. Since tariffs are a central instrument of trade policy, this analysis focuses on strategies to circumvent or minimize their impact, without considering illegal methods such as smuggling, as this is not within the scope of a legitimate analysis. Instead, we focus on legal trade practices, the use of free trade agreements, relocation of production, and other mechanisms. The current state of tariff policy is assumed as the starting point, with current calculations indicating that the US imposed additional punitive tariffs of 145 percent on Chinese goods, including high-tech and pharmaceutical products, in 2025. This had been hinted at in various trade policy scenarios under the Trump administration.
1. Use of Third Countries as Transit Points (Re-export Strategies)
One of the most effective methods to circumvent punitive tariffs is to reroute exports through third countries that have no or lower tariffs with the US. Chinese companies could first export their high-tech and pharmaceutical products to countries that are exempt from US tariffs or have free trade agreements (FTAs) with the US, such as Mexico, Canada (under USMCA), or Vietnam. There, the products could undergo minimal processing or repackaging and then be exported to the US as goods originating from that third country.
- Mechanism: According to the Rules of Origin of USMCA or other FTAs, products must undergo "substantial transformation" to be recognized as goods of the third country. For pharmaceutical products, this could include final packaging, mixing of active ingredients, or manufacturing finished products from intermediates. For high-tech products, assembly or integration of components might suffice.
- Example: A Chinese company exports pharmaceutical intermediates (e.g., active ingredients) to Mexico. There, they are processed into tablets and imported into the US as Mexican products, thereby circumventing the punitive tariffs against China.
- Advantages: Mexico and Canada are geographically close to the US, which reduces transportation costs, and they benefit from USMCA, which offers tariff-free status for qualified goods.
- Challenges: The US could tighten rules of origin or impose additional tariffs on third countries if they determine they are being used for circumvention, as has already been hinted at in previous trade disputes (e.g., Trump's criticism of Chinese investments in Mexico).
2. Relocation of Production to Third Countries
A more long-term strategy is to relocate the production of high-tech and pharmaceutical products to countries not affected by punitive tariffs. Chinese companies could establish subsidiaries or joint ventures in Southeast Asia (e.g., Vietnam, Malaysia), India, or even Europe, to export to the USA from there.
- Pharma specifics: The pharmaceutical industry requires highly regulated production facilities that comply with the standards of the U.S. Food and Drug Administration (FDA). India, as the world's leading exporter of generics, is a suitable option as it already has established infrastructure and regulatory experience. Chinese firms could cooperate with Indian partners to import active pharmaceutical ingredients (APIs) from China and complete final production in India.
- High-tech specifics: For high-tech products such as electronic components or medical technology, Vietnam could be an attractive option, as the country has become a hotspot for electronics production in recent years (e.g., Samsung's massive investments).
- Advantages: Products from these countries are not subject to China-specific punitive tariffs and could even benefit from existing trade advantages (e.g., lower tariffs for developing countries under the Generalized System of Preferences).
- Challenges: Relocation requires significant investment and time. Furthermore, the USA could expand tariffs to these countries if they notice the trend.
3. Utilization of Free Trade Zones and Warehousing Strategies
Chinese companies could utilize free trade zones (FTZs) or bonded warehouses in third countries to temporarily store their products and then export them to the USA without punitive tariffs. In FTZs, no import duties are levied as long as the goods do not enter the domestic market of the host country.
- Mechanism: High-tech and pharmaceutical products are exported to an FTZ in Panama, Singapore, or the United Arab Emirates. From there, they are shipped directly to the USA, with the country of origin labeling remaining Chinese, but the direct connection to China being obscured through clever logistics and contracts.
- Advantages: This method does not require production relocation and utilizes existing trade infrastructures.
- Challenges: The USA could introduce stricter controls to verify the actual origin of the goods, especially if they suspect that FTZs are being used for circumvention.
4. Direct Investment in the USA
Another option is for Chinese companies to establish production facilities directly in the USA to completely avoid tariffs. This would mean that high-tech and pharmaceutical products would be manufactured locally and considered U.S. products.
- Pharma example: A company like Sinopharm could build a plant in the USA to produce vaccines or generics locally, possibly in cooperation with a U.S. partner to overcome regulatory hurdles.
- High-tech example: Huawei or another technology provider could relocate component manufacturing to the USA to serve the market directly.
- Advantages: Besides avoiding tariffs, this could reduce political pressure and create jobs in the USA, aligning with "America First" policies.
- Challenges: High investment costs, strict regulatory requirements (especially in the pharmaceutical industry), and potential political rejection of Chinese investments by institutions like the Committee on Foreign Investment in the United States (CFIUS).
5. Circumvention via existing trade agreements and partners
China could leverage existing trade relationships with countries less focused on US tariff policy, such as members of ASEAN (Association of Southeast Asian Nations) or countries with bilateral agreements with the USA.
- Mechanism: Pharmaceutical products are exported to Thailand, processed there, and imported into the USA as Thai goods. Similarly, high-tech components could be routed through Malaysia or Singapore.
- Advantages: ASEAN countries often have lower production costs and could serve as a credible alternative to direct exports from China.
- Challenges: The USA could accuse China of using these countries as "proxies" and take corresponding countermeasures.
6. Supply chain and product classification adjustments
A more subtle method is adjusting the supply chain or reclassifying products to export them under less affected tariff codes (Harmonized System Codes).
- Mechanism: Instead of exporting finished pharmaceutical products, Chinese companies could supply semi-finished products or raw materials that are further processed in the USA. For high-tech, individual components could be exported instead of complete devices, which are then assembled on-site.
- Advantages: Semi-finished products often fall under different, lower tariff rates, and final assembly in the USA could create local jobs.
- Challenges: This requires coordination with US partners and could alter the cost structure.
Conclusion and assessment
The strategies outlined above offer Chinese companies several ways to bring their high-tech and pharmaceutical products into the USA without punitive tariffs, despite the new tariffs in 2025. The use of third countries like Mexico or India, as well as relocating production, appear to be the most promising approaches, as they offer both short-term flexibility and long-term stability. Direct investment in the USA could be politically advantageous but is capital-intensive and time-consuming. Free trade zones and supply chain adjustments offer additional options but are more vulnerable to intensified US controls.
The choice of strategy depends on several factors: the type of product (pharma vs. high-tech), the company's available resources, and the evolution of US trade policy. Given the dynamic nature of tariff policy under a potential Trump administration in 2025, it is likely that the US will respond to these circumvention strategies, for example, through expanded tariffs on third countries or stricter rules of origin. Nevertheless, the global interconnectedness of supply chains remains an advantage for China, enabling it to find ways into the US market despite protectionist measures. A combination of short-term re-exports and long-term production relocation is likely to be the most effective response to the tariff challenge.
